Contrast-enhanced Ultrasound Evaluation of Chemoembolization

Inclusion Criteria: * Patients \>= 21 years of age * Patient capable of making informed decisions regarding his/her treatment * Scheduled for TACE treatment of a HCC mass (lesions reported as Liver Imaging Reporting and Data Systems 4B or 5 or Organ Procurement and Transplantation Network 5a or 5b) * Negative pregnancy test in a female of child-bearing age. * Have an HCC mass viewable on grayscale B-mode ultrasound. Exclusion Criteria: * Females who are pregnant or nursing. * Patients not eligible or scheduled for TACE of a HCC mass. * Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 h after their final CEUS exam. * Patients who have received prior radioembolization (Y90) of the lesion of interest. * Patients with known or suspected cardiac shunts. * Patients with pulmonary hypertension or unstable cardiopulmonary conditions. * Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example: * Patients with unstable occlusive disease (e.g., crescendo angina) * Patients with clinically unstable cardiac arrhythmias * Patients with uncontrolled congestive heart failure (NYHA Class IV)